In this podcast, Dr. Valentin Fuster discusses a groundbreaking study examining the non-linear relationship between cardiac mortality and heat waves, focusing on how excess temperature during these events can impact heart disease death rates. The study reveals that compound heat waves, involving both day and night temperatures, significantly increase mortality risks, emphasizing the need for more precise heat wave definitions and health measures to protect vulnerable populations in a warming climate.

In this podcast, Dr. Valentin Fuster presents a study evaluating the five-year outcomes of Transcatheter Aortic Valve Replacement (TAVR) versus surgical aortic valve replacement in high-risk patients. The study shows that TAVR leads to significantly better valve performance but highlights that both procedures' long-term success is hindered by bioprosthetic valve dysfunction, underscoring the need for individualized treatment strategies and longer follow-up studies.

In this podcast, Dr. Valentin Fuster reviews a comprehensive study on the cardiovascular care of pediatric athletes, focusing on preventing sudden cardiac arrest and managing sports-related heart risks. The discussion highlights the importance of shared decision-making between healthcare providers, parents, and coaches, while addressing various heart conditions, screening strategies, and exercise recommendations for young athletes.

This interview features JACC Associate Editor Neha Pagidipati, MD, FACC, speaking with Maria Pabon, MD and Muthu Vaduganathan, MD about their study on finerenone's role in reducing new-onset atrial fibrillation in patients with cardio-kidney metabolic disease. The discussion covers the methodology and findings of a pooled analysis from three major clinical trials, highlighting finerenone's 17% risk reduction in atrial fibrillation, its potential mechanisms, and the need for greater diversity in clinical trial populations. They also touch on comparative evidence with other mineralocorticoid receptor antagonists and the broader implications for heart failure management.

Dhruv Kazi, MBBS, MS, FACC and first author Mohammed Essa, MD, discuss their newly published JACC Brief Report presented at ACC.25 on cardiac rehabilitation following myocardial infarction, with a focus on patients who experience cardiogenic shock. JACC: Associate Editor Jason H. Wasfy, MD, MPhil, FACC, asks questions to explore the significant underutilization of cardiac rehab, the impact of social determinants of health, and potential policy changes to improve access and outcomes. Join the conversation as they highlight key findings and the need for innovative solutions in cardiovascular care. #jacc #jaccjournals #acc25

In this insightful discussion, Christie Ballantyne, MD, FACC shares research on targeting APOC-III with Plozasiran to manage hypertriglyceridemia. He and JACC Associate Editor Marc P. Bonaca, MD, FACC discuss the impact on lipoprotein particle size, LDL composition, and potential cardiovascular benefits. Don't miss this deep dive into the future of lipid management and cardiovascular risk reduction – listen now and read the study in JACC: https://www.jacc.org/doi/10.1016/j.jacc.2025.03.496 #jaccjournals #jacc #acc25

Hosts Mitsuaki Sawano, MD, and Shun Kohsaka, MD, FACC, welcome Saki Ito, MD, a physician scientist at the Mayo Clinic, to discuss key topics expected at the upcoming ACC.25 in Chicago and a nuanced phenotype of aortic stenosis (AS): high-gradient AS with an aortic valve area (AVA) greater than 1.0 cm². Drawing from a recent retrospective study at Mayo Clinic, Dr. Ito examines the heterogeneous nature of this group—including patients with bicuspid valves and elevated stroke volume due to larger body size—and the potential prognostic benefit of aortic valve replacement (AVR) despite the absence of classic severity markers.

Watch here for a video interview with JACC Associate Editor Michelle Kittleson, MD, FACC, and author Mathew S. Muarer, MD, FACC, as they discuss Dr. Maurer's study published in JACC and presented at ACC.25. This exploratory analysis of HELIOS-B assessed the efficacy of vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) by subgroups of baseline heart failure severity (primarily by NYHA class and NT-proBNP levels). Vutrisiran showed evidence of benefit vs placebo on mortality, cardiovascular events, functional capacity, quality of life, and cardiac biomarkers across the range of baseline disease severities in patients enrolled in HELIOS-B, with greatest benefit observed in patients with earlier, less severe disease.

In this podcast episode, Dr. Valentin Fuster, editor emeritus of the Journal of the American College of Cardiology, presents a comprehensive summary of the April 1, 2025 issue, covering five groundbreaking studies in cardiovascular research. Key highlights include insights on mechanical vs. bioprosthetic aortic valve replacement, AI-driven screening for structural heart disease, the impact of guideline-directed medical therapy in chronic coronary artery disease, and the significance of remnant cholesterol in peripheral arterial disease.

In this episode, Dr. Valentin Fuster discusses a study comparing bioprosthetic and mechanical aortic valve replacements, revealing that mechanical valves provide a survival benefit for patients under 60, despite the inconvenience of anticoagulation. The study's findings challenge the increasing trend toward bioprosthetic valves, emphasizing that individualized patient care should remain the focus in choosing the best valve option.